Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom

References

• Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO Clinical Practice Guidelines for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009;76:S1-S130
   Google Scholar
• Ayodele OE, Alebiosu CO. Burden of chronic kidney disease: an International perspective. Adv Chronic Kidney Dis 2010;17:215-24
   PubMed Web of Science ®Google Scholar
• Stevens PE, O'Donoghue DJ, de Lusignan S, et al. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int 2007;72:92-9
   PubMed Web of Science ®Google Scholar
• de Lusignan S, Tomson C, Harris K, et al. Creatinine fluctuation has a greater effect than the formula to estimate glomerular filtration rate on the prevalence of chronic kidney disease. Nephron Clin Pract 2011;117:c213-24
   Web of Science ®Google Scholar
• Kundhal K, Lok CE. Clinical epidemiology of cardiovascular disease in chronic kidney disease. Nephron Clin Pract 2005;101:c47-52
   PubMed Web of Science ®Google Scholar
• Yoshino M, Kuhlmann MK, Kotanko P, et al. International differences in dialysis mortality reflect background general population atherosclerotic cardiovascular mortality. J Am Soc Nephrol 2006;17:3510-9
   PubMed Web of Science ®Google Scholar
• Dor A, Pauly MV, Eichleay MA, et al. End-stage renal disease and economic incentives: the International Study of Health Care Organization and Financing (ISHCOF). Int J Health Care Finance Econ 2007;7:73-111
   PubMedGoogle Scholar
• Glynn LG, Reddan D, Newell J, et al. Chronic kidney disease and mortality and morbidity among patients with established cardiovascular disease: a West of Ireland community-based cohort study. Nephrol Dial Transplant 2007;22:2586-94
   Google Scholar
• USRDS. Atlas of chronic kidney disease and end-stage renal disease in the United States. United States Renal Data Service Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2011
   Google Scholar
• Hage FG, Venkataraman R, Zoghbi GJ, et al. The scope of coronary heart disease in patients with chronic kidney disease. J Am Coll Cardiol 2009;53:2129-40
   PubMed Web of Science ®Google Scholar
• Ramos AM, Albalate M, Vazquez S, et al. Hyperphosphatemia and hyperparathyroidism in incident chronic kidney disease patients. Kidney Int Suppl 2008;111:S88-93
   Google Scholar
• Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007;71:31-8
   PubMed Web of Science ®Google Scholar
• Hsu CY, Chertow GM. Elevations of serum phosphorus and potassium in mild to moderate chronic renal insufficiency. Nephrol Dial Transplant 2002;17:1419-25
   Google Scholar
• Bellasi A, Mandreoli M, Baldrati L, et al. Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction. Clin J Am Soc Nephrol 2011;6:883-91
   PubMed Web of Science ®Google Scholar
• Kanbay M, Goldsmith D, Akcay A, et al. Phosphate - the silent stealthy cardiorenal culprit in all stages of chronic kidney disease: a systematic review. Blood Purif 2009;27:220-30
   PubMed Web of Science ®Google Scholar
• Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18
   PubMed Web of Science ®Google Scholar
• Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005;67:1179-87
   PubMed Web of Science ®Google Scholar
• Smith DH, Johnson ES, Thorp ML, et al. Outcomes predicted by phosphorous in chronic kidney disease: a retrospective CKD-inception cohort study. Nephrol Dial Transplant 2010;25:166-74
   Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1-201
   Google Scholar
• Isakova T, Gutierrez OM, Chang Y, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009;20:388-96
   PubMed Web of Science ®Google Scholar
• Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52:519-30
   PubMed Web of Science ®Google Scholar
• Danese MD, Belozeroff V, Smirnakis K, et al. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1423-9
   PubMed Web of Science ®Google Scholar
• Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52
   PubMed Web of Science ®Google Scholar
• Burke SK, Dillon MA, Hemken DE, et al. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients. Adv Ren Replace Ther 2003;10:133-45
   PubMedGoogle Scholar
• Russo D, Miranda I, Ruocco C, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 2007;72:1255-61
   PubMed Web of Science ®Google Scholar
• Bolland MJ, Grey A, Avenell A, et al. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 2011;342:d2040-40
   PubMed Web of Science ®Google Scholar
• Delmez J, Block G, Robertson J, et al. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol 2007;68:386-91
   PubMed Web of Science ®Google Scholar
• Fan S, Ross C, Mitra S, et al. A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis. Nephrol Dial Transplant 2009;24:3794-9
   PubMed Web of Science ®Google Scholar
• Navaneethan SD, Palmer SC, Vecchio M, et al. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Syst Rev 2011;(2):CD006023
   Google Scholar
• Navaneethan SD, Palmer SC, Craig JC, et al. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 2009;54:619-37
   PubMed Web of Science ®Google Scholar
• Hutchison AJ, Smith CP, Brenchley PE. Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol 2011;7:578-89
   PubMed Web of Science ®Google Scholar
• Ketteler M. Phosphate Metabolism in CKD Stages 3-5: dietary and pharmacological control. Int J Nephrol 2011;2011:970245
   Google Scholar
• Di Iorio B, Bellasi A, Russo D. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 2012;7:487-93
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. National Institute for Health and Clinical Excellence. 2008
   Google Scholar
• National Health Service (NHS). NHS Reference Cost Database. National Health Service, Department of Health. 2010
   Google Scholar
• British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary (BNF). London: BMA. 2011
   Google Scholar
• Gudex CM. Health-related quality of life in endstage renal failure. Qual Life Res 1995;4:359-66
   PubMed Web of Science ®Google Scholar
• Leese B, Hutton J, Maynard A. A comparison of the costs and benefits of recombinant human erythropoietin (epoetin) in the treatment of chronic renal failure in 5 European countries. Pharmacoeconomics 1992;1:346-56
   PubMedGoogle Scholar
• Gorodetskaya I, Zenios S, McCulloch CE, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int 2005;68:2801-8
   PubMed Web of Science ®Google Scholar
• Revicki DA, Rothman M, Luce B. Health-related quality of life assessment and the pharmaceutical industry. Pharmacoeconomics 1992;1:394-408
   PubMedGoogle Scholar
• Ansell D, Feehally J, Fogarty D, et al. UK Renal Registry 2009: 12th Annual Report of the Renal Association. Nephron Clin Pract 2010;115(1 Suppl)
   Google Scholar
• Mactier R, Hoenich N, Breen C. The Renal Association Guidelines - Haemodialysis. The Renal Association. 2009
   Google Scholar
• Grima DT, Bernard LM, Dunn ES, et al. Cost-effectiveness analysis of therapies for chronic kidney disease patients on dialysis: a case for excluding dialysis costs. Pharmacoeconomics 2012;30:981-9
   PubMed Web of Science ®Google Scholar
• St Peter WL, Liu J, Weinhandl E, et al. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 2008;51:445-54
   PubMed Web of Science ®Google Scholar
• St Peter WL, Fan Q, Weinhandl E, et al. Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data. Clin J Am Soc Nephrol 2009;4:1954-61
   PubMed Web of Science ®Google Scholar
• Baboolal K, McEwan P, Sondhi S, et al. The cost of renal dialysis in a UK setting—a multicentre study. Nephrol Dial Transplant 2008;23:1982-9
   PubMed Web of Science ®Google Scholar
• Revicki DA. Relationship between health utility and psychometric health status measures. Med Care 1992;30:MS27-82
   Google Scholar